Pengbo Jiang1, Athena Christakos1, Mina Fam1, Hossein Sadeghi-Nejad2. 1. Department of Urology, Rutgers-New Jersey Medical School, Newark, NJ, USA. 2. Department of Urology, Rutgers-New Jersey Medical School, Newark, NJ, USA. ; Center for Male Reproductive Medicine & Microsurgery, Hackensack University Medical Center, Hackensack, NJ, USA.
Abstract
PURPOSE: Although penile duplex Doppler ultrasonography (PDDU) is a common and integral procedure in a Peyronie's disease workup, the intracavernosal injection of vasoactive agents can carry a serious risk of priapism. Risk factors include young age, good baseline erectile function, and no coronary artery disease. In addition, patients with Peyronie's disease undergoing PDDU in an outpatient setting are at increased risk given the inability to predict optimal dosing. The present study was conducted to provide support for a standard protocol of early administration of phenylephrine in patients with a sustained erection after diagnostic intracavernosal injection of vasoactive agents to prevent the deleterious effects of iatrogenic priapism. MATERIALS AND METHODS: This was a retrospective review of Peyronie's disease patients who received phenylephrine reversal after intracavernosal alprostadil (prostaglandin E1) administration to look at the priapism rate. Safety was determined on the basis of adverse events reported by subjects and efficacy was determined on the basis of the rate of priapism following intervention. RESULTS: Patients with Peyronie's disease only had better hemodynamic values on PDDU than did patients with Peyronie's disease and erectile dysfunction. All of the patients receiving prophylactic phenylephrine had complete detumescence of erections without adverse events, including no priapism cases. CONCLUSIONS: The reversal of erections with phenylephrine after intracavernosal injections of alprostadil to prevent iatrogenic priapism can be effective without increased adverse effects.
PURPOSE: Although penile duplex Doppler ultrasonography (PDDU) is a common and integral procedure in a Peyronie's disease workup, the intracavernosal injection of vasoactive agents can carry a serious risk of priapism. Risk factors include young age, good baseline erectile function, and no coronary artery disease. In addition, patients with Peyronie's disease undergoing PDDU in an outpatient setting are at increased risk given the inability to predict optimal dosing. The present study was conducted to provide support for a standard protocol of early administration of phenylephrine in patients with a sustained erection after diagnostic intracavernosal injection of vasoactive agents to prevent the deleterious effects of iatrogenic priapism. MATERIALS AND METHODS: This was a retrospective review of Peyronie's diseasepatients who received phenylephrine reversal after intracavernosal alprostadil (prostaglandin E1) administration to look at the priapism rate. Safety was determined on the basis of adverse events reported by subjects and efficacy was determined on the basis of the rate of priapism following intervention. RESULTS:Patients with Peyronie's disease only had better hemodynamic values on PDDU than did patients with Peyronie's disease and erectile dysfunction. All of the patients receiving prophylactic phenylephrine had complete detumescence of erections without adverse events, including no priapism cases. CONCLUSIONS: The reversal of erections with phenylephrine after intracavernosal injections of alprostadil to prevent iatrogenic priapism can be effective without increased adverse effects.
Entities:
Keywords:
Alprostadil; Male urogenital diseases, Peyronie's disease; Phenylephrine; Priapism
Authors: Drogo K Montague; Jonathan Jarow; Gregory A Broderick; Roger R Dmochowski; Jeremy P W Heaton; Tom F Lue; Ajay Nehra; Ira D Sharlip Journal: J Urol Date: 2003-10 Impact factor: 7.450
Authors: Martin Gelbard; Wayne J G Hellstrom; Chris G McMahon; Laurence A Levine; Ted Smith; James Tursi; Gregory Kaufman; Irwin Goldstein Journal: J Sex Med Date: 2013-09-24 Impact factor: 3.802
Authors: Andrea Salonia; Suks Minhas; Paolo Capogrosso; Kostas Dimitropolous; Giorgio Ivan Russo; Tharu Tharakan; Uros Milenkovic; Andrea Cocci; Luca Boeri; Murat Gül; Carlo Bettocchi; Joana Carvalho; Arif Kalkanlı; Giovanni Corona; Georgios Hatzichristodoulou; Hugh T Jones; Ates Kadioglu; Juan Ignacio Martinez-Salamanca; Vaibhav Modgil; Ege Can Serefoglu; Paolo Verze Journal: Int J Impot Res Date: 2022-08-22 Impact factor: 2.408
Authors: Bruno Nascimento; Eduardo P Miranda; Jean-Etienne Terrier; Felipe Carneiro; John P Mulhall Journal: J Sex Med Date: 2020-07-03 Impact factor: 3.937